Company intelligence / Profile preview

DefEYE

Sarasota, Florida, United States

Ownership: Private
Development stage: Other

Overview

DefEYE is a privately held ophthalmic biologics company specializing in decellularized amniotic and placenta-derived tissue products. Its lead commercial products, Biovance, Biovance 3L Ocular, and Interfyl, are used for ocular surface repair, advanced ocular surface diseases, and post-surgical application. Clinical research supports the use of Biovance 3L Ocular over conventional approaches for advanced ocular surface diseases.

Therapeutic areas: OphthalmologyOther
Modalities: BiologicDecellularized tissue product
Industry: Biotech

Partnerships

Celularity

Beyond the preview

Go deeper on DefEYE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DefEYE.

Explore the full profile